Telomerase activation is considered to be a critical step in cancer progression due to its role in cellular immortalization. The prevalence of telomerase expression in human cancers makes it an attractive candidate for new mechanism-based targets for cancer therapy. The selective killing of cancer cells can be achieved by gene-directed enzyme pro-drug therapy (GDEPT). In this study we have tested the feasibility of using the transcriptional regulatory sequences from the hTERT and hTR genes to regulate expression of the bacterial nitroreductase enzyme in combination with the pro-drug CB1954 in a suicide gene therapy strategy. hTERT and hTR promoter activity was compared in a panel of 10 cell lines and showed a wide distribution in activity; low activity was observed in normal cells and telomerasenegative immortal ALT cell lines, with up to 300-fold higher activity observed in telomerase positive cancer lines. Placing the nitroreductase gene under the control of the telomerase gene promoters sensitized cancer cells in tissue culture to the pro-drug CB1954 and promoter activity was predictive of sensitization to the pro-drug (2 ± 20-fold sensitization), with cell death restricted to lines exhibiting high levels of promoter activity. The in vivo relevance of these data was tested using two xenograft models (C33a and GLC4 cells). Signi®cant tumour reduction was seen with both telomerase promoters and the promoter-speci®c patterns of sensitization observed in tissue culture were retained in xenograft models. Thus, telomerase-speci®c suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene (2001) 20, 7797 ± 7803.
Keywords: telomerase; hTERT; hTR; gene therapy; nitroreductase; GDEPT A major drawback of conventional cytotoxic chemotherapy agents for the treatment of cancer is the lack of selectivity for tumour cells resulting in toxicity to normal healthy tissues. Molecular therapies have consequently been designed to target dierences between cancer and normal cells (Gibbs, 2000) . Telomerase activation is considered to be a critical step in cancer progression due to its role in cellular immortalization. The level and frequency of telomerase activity and component gene expression in cancers when compared to normal cells makes telomerase an attractive target for anticancer strategies (Nowak and Chrapusta, 1998; Sharma et al., 1997; Shay et al., 2001; Urquidi et al., 1998; White et al., 2001; Yi et al., 1999) . Indeed, the inhibition of telomerase in cancer cells in tissue culture can lead to cell death, strongly supporting the eorts to develop telomerase inhibitors for clinical use (White et al., 2001) . Several potential therapeutic strategies have been proposed with the telomere or telomerase enzyme as the molecular target. One potential drawback of these strategies is the phenotypic lag; that is, the number of cell divisions necessary before inhibition of telomerase can lead to sucient shortening of the telomere to give rise to a phenotypic eect (White et al., 2001 ). An alternative strategy is to exploit tumour-speci®c telomerase gene expression to target gene therapy vectors to cancer cells, thus causing rapid cell kill (Harrington et al., 2000; Nettelbeck et al., 2000) . Recently there has been considerable interest in the development of telomerasedirected gene therapy, including systems designed to increase the therapeutic index by selective expression in cancer cells of genes encoding enzymes involved in prodrug activation (Abdul-Ghani et al., 2000; Gu et al., 2000; Koga et al., 2000; Majumdar et al., 2001) .
Human telomerase activity can be reconstituted in vitro by the essential RNA subunit, hTR, and the catalytic protein component coded for by the hTERT gene . The recent accumulation of detailed knowledge on telomerase gene regulation suggests that both the human telomerase reverse transcriptase gene (hTERT) and the telomerase RNA gene (hTR) are controlled at least in part at the transcriptional level (Abdul-Ghani et al., 2000; Gu et al., 2000; Gunes et al., 2000; Hoare et al., 2001; Koga et al., 2000; Majumdar et al., 2001; Yi et al., 1999; Zhao et al., 2000) . Studies from our group and others suggest that the hTR gene is expressed at high levels in cancer cells, yet can also be detected at low levels in some normal tissues (Heine et al., 1998; Hiyama et al., 1999; Maitra et al., 1999; Park et al., 1999; Sarvesvaran et al., 1999; Soder et al., 1998; Stanta et al., 1999; Weng et al., 1997; Wisman et al., 2000; Yashima et al., 1998) . The hTERT gene is expressed at low levels in cancer cells and is generally undetectable in normal cells Kolquist et al., 1998) . Thus for both genes there is a clear dierential and therefore both gene promoters may be of use for genetic therapies designed to target therapeutic genes to tumours, via tumour speci®c gene expression (AbdulGhani et al., 2000; Gu et al., 2000; Koga et al., 2000; Majumdar et al., 2001) . These initial studies have highlighted the need for more information on telomerase promoter activity in dierent cell types and on its ability to drive therapeutic genes.
A number of enzyme-pro-drug systems have been proposed for cancer gene therapy (Greco and Dachs, 2001 ). This study concentrated on the bacterial nitroreductase (NTR) system for the following reasons. The pro-drug, CB1954, is a monofunctional-alkylating agent that is poorly metabolized in human cells and thus has a low toxicity. The bacterial nitroreductase enzyme from E. coli is however able to convert CB1954 to its active form. The active drug introduces poorly repaired interstrand cross-links into DNA and these lesions kill dividing and non-dividing cells by inducing apoptosis. In addition the active metabolite is diusible and membrane permeable resulting in an ecient bystander eect. Taken together, these attributes make CB1954/NTR an extremely potent yet safe form of gene-directed enzyme pro-drug therapy (GDEPT) (Bailey and Hart, 1997; Bailey et al., 1996; Greco and Dachs, 2001; Weedon et al., 2000) .
The purpose of this study was to generate a family of gene therapy vectors using the transcriptional regulatory regions from the hTERT and hTR genes to drive expression of the bacterial nitroreductase gene (NTR), and to assess the ability of the telomerase gene therapy vectors to sensitize cancer cells to the pro-drug CB1954.
In order to assess transgene expression from the hTERT and hTR promoters in various cells, plasmid vectors expressing the luciferase reporter gene driven by a 536 bp hTERT promoter fragment (nucleotide position 2834 ± 3369 in GenBank Accession number AB016767) (Takakura et al., 1999) , or an 867 bp hTR promoter fragment described previously, (nucleotide position 1 ± 867 in GenBank Accession number AF047386), were used (Zhao et al., 1998 (Zhao et al., , 2000 .
As expected, the hTERT promoter showed highest activity in the telomerase positive cancer cell lines A2780, Colo320DM, GLC4 and C33a ( Figure 1a) . Consistent with previous studies, little or no promoter activity could be detected in the telomerase negative normal human ®broblasts (WI38, IMR90), or the telomerase negative ALT immortal cell lines, SKLU-1 and SUSM-1 (Abdul-Ghani et al., 2000; Gu et al., 2000; Hoare et al., 2001; Koga et al., 2000; Majumdar et al., 2001) . Other telomerase positive tumour cell lines (A549, 5637), exhibited low transcriptional activity only marginally above the level of normal and ALT-lines. Interestingly, low hTERT promoter activity has also been described in the MCF7, U373 and U87 cancer cell lines demonstrating the range of hTERT promoter activity in dierent cancer cells (Koga et al., 2000) .
The telomerase RNA component promoter showed highest activity in the telomerase positive cancer cell lines, A2780, Colo320dm, GLC4 and C33a cells (Figure 1b) . In general the hTR promoter was more active than hTERT. As with the hTERT promoter only low hTR promoter activity could be detected in the telomerase negative normal human ®broblasts (WI38, IMR90) and the telomerase negative ALT immortal cell lines, SKLU-1 or SUSM-1. Although the range of activity in normal and ALT lines was greater for the hTR promoter than that observed with the hTERT promoter, there was still a dierential between these cell types and the highly active cancer cell lines, (Figure 1b ). These data con®rm and extend the data on low hTR promoter activity in normal cells and ALT cells described by others (Abdul-Ghani et al., 2000) . The telomerase positive lung tumour cell line, A549, exhibited low hTR transcriptional activity comparable to that of normal and ALT-line level.
In order to gain a more direct measure of promoter speci®city and strength in relation to therapeutic questions we have generated of a family of gene therapy vectors using the transcriptional regulatory regions from the hTERT and hTR genes to drive the bacterial nitroreductase gene (NTR), (Table 1) . The constructs were introduced into recipient cell lines by stable transfection in order to allow accurate comparisons to be made between vectors and to allow for the development of xenograft models. A total of eight parental lines were used and sub-lines were derived from each gene therapy vector shown in Table 1 . Thus a total of 32 lines with stable integration of the vectors were selected. The same cell lines used for the luciferase reporter assays were used with the exception of the two mortal cell strains (WI38, IMR90) as stable clones could not be selected and analysed due to the ®nite replicative lifespan of these cells. However, given the observation that ALT lines have promoter activity in the same range as normal cells, it is not unreasonable to use these as surrogates for normal mortal cells for the purposes of relating promoter activity to cellular sensitization.
To test the selectivity and eciency of target cell sensitization by the telomerase gene therapy vectors (pd2ntr-hTERT, pd2ntr-hTR), cell lines for each promoter construct were evaluated in pro-drug sensitization assays. Cell lines containing the control vectors either without a promoter (pd2ntr-basic1), or with the NTR gene driven by the CMV promoter (pd2ntr-CMV), were also evaluated. Cells were treated with varying concentrations of CB1954 and Figure 1c ,d shows representative dose response curves for the C33a and GLC4 cell lines containing the telomerase gene therapy vectors. The concentration of CB1954 required to give a 50% reduction in growth, (IC 50 ) was Figure 1 Activities of the (a) hTERT and (b) hTR promoters in cancer, ALT and mortal cell lines quanti®ed by luciferase assay, (Zhao et al., 1998 (Zhao et al., , 2000 . Cell lines were transfected in 6-well plates using Qiagen superfect transfection reagent and 3 mg of the luciferase reporter constructs pLh2023 (hTR promoter) or pLhTERT19 (hTERT promoter). Forty-eight hours post-transfection, cells were lysed and assayed for luciferase activity (Promega luciferase assay system). Protein equivalents (2.5 mg) were calculated by using Bio-Rad protein assay reagent. All cells were transfected alongside 5637 cells for normalization. Transfection eciencies were checked both by co-transfection with an SV40-SEAP reporter (Clontech) and by semi quantitative PCR screening for the presence of the luciferase gene in post-transfected nuclei. All transfections were repeated at least three times. Human cell lines used in this study are A2780 (ovarian adenocarcinoma), Colo320dm (colorectal adenocarcinoma), GLC4 (small cell lung carcinoma), C33a (cervical carcinoma), 5637 (bladder carcinoma), A549 (lung adenocarcinoma), SUSM-1 (telomerase negative in vitro immortalized ®broblast), SKLU-1 (telomerase negative lung adenocarcinoma), IMR90 (telomerase negative foetal lung ®broblast) and WI-38 (telomerase negative foetal lung ®broblast). (c) and (d). Representative cytotoxicity curves for the cell lines C33a (c) and GLC4 (d) stably transfected with nitroreductase expression plasmids. Cells were transfected with plasmids carrying the nitroreductase gene either in a basic, promoterless vector, or driven by CMV, hTR or hTERT promoters (Table 1) . Forty-eight hours post-transfection, cells were selected in 1 mg/ml G418 (Gibco). Following the appearance of stable foci, pools of clones were collected and used for MTT (Sigma) assays to quantify cytotoxicity of CB1954. For MTT assay, typically 700 cells were seeded per well in 96 well plates in triplicate and allowed to proliferate for 2 days prior to the addition of CB1954. CB1954, typically in the range 100 mM to 6 nM was added for 24 h and 3 ± 4 days later surviving fractions were calculated by 4 h incubation with MTT. Analyses were performed with a Molecular Devices plate reader and analysis package (Softmax 2.32). All assays were performed at least three times, (Mistry et al., 2001) . (e). Sensitization of cancer and ALT cell lines to CB1954 by stable expression of bacterial nitroreductase. Cell lines SKLU-1; SUSM-1; 5637; A2780; C33a; A549; GLC4 and COLO320dm, described above, were stably transfected with nitroreductase plasmids and cytotoxicity curves obtained as described in (c) and (d). IC 50 values were estimated in individual experiments from triplicate curves and the fold dierence (sensitization) between IC 50 values for the basic construct and for those carrying hTR and hTERT promoters was calculated for each cell line. Results shown are the means and standard errors derived from three independent experiments for each cell line, (Mistry et al., 2001) determined by MTT assay for all lines (Table 2 ) and the fold sensitization of the cell lines harbouring the telomerase gene therapy vectors determined relative to the promoterless NTR vector, pd2ntr-basic1 ( Figure  1e ). As can be seen from Figure 1e and Table 2 , both the hTERT and hTR promoters were able to drive sucient expression of the NTR gene in A2780, C33a, GLC4 and Colo320dm to achieve a 5 ± 20-fold sensitization to CB1954. As predicted from the luciferase reporter assays, cell lines with low promoter activity (Figure 1a,b) such as the ALT lines, SKLU-1 and SUSM-1 were not sensitized to the pro-drug. In addition, the 5637 bladder carcinoma and A549 lung lines also have low hTERT promoter activity and are not eciently sensitized to CB1954. However, the hTR promoter activity in A549 cells is sucient to result in a ®vefold sensitization to CB1954 whilst slightly higher hTR activity in 5637 cells does not result in sensitization. These data suggest that other factors including cell speci®c responses to the DNA damage induced by the active alkylating agent are also important in determining response.
The data above suggest that the telomerase-NTR gene therapy vectors may be of use in treating human cancer. It was therefore important to establish in vivo xenograft models to test the functional signi®cance of sensitization of cells in tissue culture to suppression of tumour growth in vivo (Plumb et al., 2000) . To determine the in vivo anti-tumour eect of the hTERT-NTR and hTR-NTR gene therapy vectors, stably transfected cervical cancer C33a cells and smallcell lung cancer GLC4 cells were injected into nude mice. On tumour take, mice were treated with a single dose of either CB1954 or saline control and tumour growth recorded over 6 days. The highest dose of drug tested was 80 mg/kg and at this dose no toxicity to the animals was observed.
No tumour regression was observed in mice carrying C33a cells stably transfected with the basic control vector (Figure 2a) . Tumour regression was observed in mice carrying C33a cells transfected with the pd2ntr-CMV vector (100% reduction, Figure 2b) , the pd2ntr-hTR vector (63% reduction in tumour volume, Figure  2c) , and the pd2ntr-hTERT vector (76% reduction in tumour volume, Figure 2d ). It is of interest to note that the promoter-speci®c pattern of tumour regression observed for the C33a xenografts (Figure 2a ± d) mirrors the promoter-speci®c pattern of sensitization when the cells are exposed to CB1954 as a monolayer in tissue culture (Figure 1c) , with the CMV driven vector generating the best response and the two telomerase promoters showing similar responses and lying between the CMV and Basic control vector.
A second xenograft model was tested using the small-cell lung cancer cell line, GLC4. Minor tumour regression was observed in mice carrying GLC4 cells stably transfected with the basic control vector (26% reduction in tumour volume). This result was expected as the GLC4 parental line was found to be partially sensitive to the parental CB1954 prodrug in our sensitization assays (see Table 2 and the cytotoxicity curves in Figure 1d ). This intrinsic sensitivity to the pro-drug allowed us to lower the dose of CB1954 administered to the mice to 40 mg/kg. As seen with GLC4 cells in tissue culture (Figure 1e ), the telomerase promoters were active in the xenograft model and resulted in sensitization to the pro-drug. Tumour regression was observed in mice carrying GLC4 cells transfected with the pd2ntr-CMV vector (66% reduction in tumour volume, Figure 2f ), the pd2ntr-hTR Cytotoxicity of CB1954 in cell lines each stably transfected with one of the nitroreductase gene therapy vectors was quanti®ed by MTT assay and IC 50 values (mM) were determined using the Softmax 2.32 package (Molecular Devices), (Mistry et al., 2001) . For each experiment, IC 50 values for each construct were determined by the mean 50% y-intercept value of triplicate cytotoxity curves. Data shown are the means and standard errors (shown in brackets) derived from three independent experiments for each cell line cells were injected subcutaneously into the¯anks of athymic female nude mice. After 10 ± 15 days when the mean tumour diameter was at least 0.5 cm, animals were randomized into groups of six for experiments. CB1954 was administered on day 0. Mice were weighed daily, and tumour volumes estimated by calliper measurements, (volume=d 3 6p/6). All animal experimentation was performed to United Kingdom Home Oce Regulations and the UK CCCR guidelines were adhered to at all times, (Mistry et al., 2001; Plumb et al., 2000) . Figure 2g) , and the pd2ntr-hTERT vector (97% reduction in tumour volume, Figure 2h) . As with the C33a model, the promoter-speci®c pattern of tumour regression observed for the GLC4 xenografts (Figure 2e ± h ) mirrors the pattern of promoter-speci®c sensitization when the cells are exposed to CB1954 in tissue culture (Figure 1d) , with the two telomerase promoters showing better responses, than the CMV driven vector.
The data presented in the current study suggest that telomerase promoter activity is a major determinant of cellular response to CB1954 pro-drug therapy and that the dierential sensitivity observed between promoters in tissue culture is retained in vivo. Thus, telomerase gene promoter activity is predictive of GDEPT speci®city and eciency both in vitro and in vivo.
A major challenge facing the routine use of gene therapy in the clinic is achieving tumour speci®c treatment. This can be realized at a number of levels including tumour speci®c delivery and restriction of transgene expression to the cancer (Nettelbeck et al., 2000; Vile et al., 1998) . At present there are very few reliable methods for restricting delivery of vectors to cancer cells, and so the use of tumour-selective gene promoters to restrict the expression of a therapeutic gene to the cancer cells is an attractive option (Harrington et al., 2000; Nettelbeck et al., 2000) . There is now a growing list of tumour speci®c promoters that are only active in selective groups of tumours such as breast or prostatic cancer (Harrington et al., 2000; Nettelbeck et al., 2000) . In contrast, telomerase gene promoters should have the advantage of displaying activity over a broad range of malignancies. Indeed, in the current study we have examined expression in cell lines from lung, colon, ovarian, bladder and cervical cancer.
The data presented contributes to the emerging picture of telomerase gene regulation and its therapeutic applications (Sarvesvaran et al., 1999; White et al., 2001) . The simple concept that telomerase is either on or o in cells is gradually being replaced by a rather more complex picture of regulated expression and a continuous range of activity. Thus, a detailed understanding of telomerase gene regulation will be required for gene therapy applications (Hoare et al., 2001; Sarvesvaran et al., 1999; Soder et al., 1998; Zhao et al., 2000) . Whilst telomerase-directed gene therapy is an extremely exciting prospect, the complexity of telomerase biology suggests that it may not be universally applicable. A consistent observation is that telomerase gene expression and activity can vary greatly even among cancers (Abdul-Ghani et al., 2000; Gu et al., 2000; Hoare et al., 2001; Koga et al., 2000; Soder et al., 1998; Takakura et al., 1999) . However, it is clear that cancers with high transcriptional activity are ideal candidates for telomerase-directed gene therapy. This is encouraging for human clinical trials as it is predicted that normal cells will have lower promoter activity than cancer cells and will be relatively spared. Nevertheless, combining the transcriptional restriction conferred by the telomerase promoters with other layers of selectivity including delivery and appropriate pro-drug dosing will be essential to the development of an optimized telomerase-directed gene therapy package.
